Stiefel Laboratories Inc. is an American dermatological pharmaceutical company, with its global headquarters in Research Triangle Park, North Carolina.

As the product line grew and diversified beyond medicinal soaps, the company was renamed Stiefel Laboratories, Inc.[7] In 1948, the Stiefel Medicinal Soap Company worked with dermatologists to develop the Oilatum family of products, which treat dry skin and atopic dermatitis.

During the 1960s, sales and manufacturing operations expanded to include Canada, Puerto Rico, Germany, Hong Kong, the United Kingdom, Costa Rica, the Philippines, Ireland and other locations.

[7] During the 1980s, Stiefel's first research and development facility outside of the US was established in 1985 in Slough, a town near the company's United Kingdom headquarters.

The company's operations continued to expand and by the 1990s Stiefel Laboratories had subsidiaries in more than 30 countries and relationships with distributors in 70 others.

By the end of the decade, factories were operating in Ireland, Brazil, Singapore and Mexico, supplying markets around the world.

[8] William D. (Bill) Humphries was promoted to president of Stiefel Laboratories, Inc., the privately held dermatology company in 2008.

[11] Stiefel launched MaxClarity[12] and received FDA approval of two Rx products in the United States,[13] Sorilux Foam and Veltin Gel in 2010.

In 2013, GSK discontinued the UK version of Stiefel's popular skin drying treatment, Zeasorb.